Option chain shows key data for 36KR Holdings's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for 36KR Holdings.

36KR Holdings (NASDAQ:KRKR) Stock, Option Chain

36KR Holdings

36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.

Trading Charts on a Display

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

AMIX

AREB

AVXL

CHGG

CNTM

DATS

GRNQ

GROM

KRKR

MTCH

OPEN

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SIEB

UAVS

Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

movers image

Intraday Update

AAGR

ADTN

ALUR

APLD

ASAN

BNAI

CABA

CDMO

CIFR

CLOV

CRKN

DMTK

GOSS

IPDN

KAVL

MBIO

MINM

MOLN

ORGS

RELI

SHCR

SMTK

SPEC

SRPT

SWBI

TPHS

TREX

WAVE

ZCAR

Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

earnings

Penny Stocks

36Kr Holdings shares are trading higher Friday after the company announced it has entered into a strategic partnership with SenseTime. Here&#39;s a look at what to know: 

Why 36Kr Stock Is Up Today

36Kr Holdings Inc. - American Depositary Shares

36KR Holdings Inc

U.S. stocks could get off to a positive start on Monday amid upbeat investor sentiment spurred the Dow Jones to <a href="https://www.benzinga.com/24/11/42157447/dow-settles-at-record-high-investor-sentiment-improves-fear-greed-index-remains-in-greed-zone">close at a new record high</a> on Friday.
Donald Trump's Treasury Secretary pick, Scott Bessent, has been cheered by investors. The hedge fund manager<a href="https://www.benzinga.com/news/24/11/42158330/trumps-treasury-secretary-pick-scott-bessent-says-a-global-economic-reordering-is-on-the-way-argues-president-elects-policies-will-lead-to-an-economic-lollapalooza"> told the Wall Street Journal</a> in an interview that he will make Trump's first-term tax cuts permanent, while also eliminating taxes on tips, social security benefits, and overtime pay, fulfilling the President-elect's election promises.
Expectations of a further 25 basis point rate cut in December have fallen to just 56% now, down from 75% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.58%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.49%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.68%</td>
</tr>
<tr>
<td>R2K</td>
<td>1.12%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.54% to $598.72 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.64% to $509.01, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Cues From Last Week:
Major indices on Wall Street recorded gains last week, with the Dow gaining around 2% and the S&amp;P 500 adding around 1.7%. The tech-heavy Nasdaq also registered gains to close up by nearly 1.6%, despite volatility as investors digested Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) earnings.
On the economic data front, the S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.
The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.
Most sectors on the S&amp;P 500 closed on a positive note, with industrials, financials, and consumer discretionary stocks recording the biggest gains on Friday.
However, utilities and communication services stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Week&#8217;s Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.64%</td>
<td>19,003.65</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.7%</td>
<td>5,969.34</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>2.18%</td>
<td>44,296.51</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>4.54%</td>
<td>2,406.67</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Wells Fargo analysts have expressed optimism about food inflation cooling down further over the coming weeks, but that it could be less noticeable now than it has been over the last two years.
"Few Americans may include a slower pace of food price growth on their list of things to be grateful for this year, but our team does expect consumer price inflation for food to continue to quiet down over time—just less noticeably than has been seen over the past two years," the analysts said in a recent note.
Ryan Detrick, chief market strategist at Carson Group, continued to remain bullish on equities.
"Various advance/decline lines show no major signs of deterioration. This continues to suggest the bull market is alive and well."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Great chart from <a href="https://twitter.com/HumbleStudent?ref_src=twsrc%5Etfw">@HumbleStudent</a> here. Various advance/decline lines show no major signs of deterioration. This continues to suggest the bull market is alive and well. Credit spreads will expand and this will weaken when the trend changes. We aren&#39;t there. <a href="https://t.co/CR0APJjCBz">pic.twitter.com/CR0APJjCBz</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1860724216695267673?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He added that investors who expect a correction after the S&amp;P 500 gained 20% for two years in a row do not have history on their side. In eight of the previous such instances, the S&amp;P 500 gained an average of 12.3% in the third year, according to data compiled by Detrick.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Up 20% two years in a row? Not saying the next year can&#39;t be red, but if this is why you are bearish, history isn&#39;t on your side. <a href="https://t.co/XXDMAszm8X">pic.twitter.com/XXDMAszm8X</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1860829081299800536?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Nathan Peterson, Director of Derivatives Analysis at the Schwab Center for Financial Research, laid <a href="https://www.schwab.com/learn/story/weekly-traders-outlook/">out</a> the thesis for market movements for the next week.
"Taking everything into consideration, bullish seasonality, bullish technicals, a strong fundamental backdrop and a friendly Fed leave me in the bullish camp for next week," Peterson said.
This week will have a shorter trading window due to Thanksgiving, which could mean lower volume but higher volatility.
"From a seasonality perspective, November is a bullish month for stocks and &#8216;Thanksgiving Week&#8217; tends to be an up week more often than not."
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How To Trade Futures</a>
Upcoming Economic Data
This week's economic calendar is not as packed as last week's due to Thanksgiving.
<ul>
<li>On Tuesday, the S&amp;P Case-Shiller home price index for 20 cities will be released at 9 a.m. ET.</li>
<li>Data on consumer confidence and new home sales will be released at 10 a.m. ET.</li>
<li>The minutes of the Fed&#8217;s November FOMC meeting will be released at 2 p.m. ET.</li>
<li>On Wednesday, initial jobless claims, advanced durable goods orders, U.S. trade balance, retail and wholesale inventories, and the first revision of GDP will be released at 8:30 a.m. ET.</li>
<li>Chicago Business Barometer (PMI) will be released at 9:45 a.m. ET.</li>
<li>Nominal personal income and spending data will be released at 10 a.m. ET.</li>
<li>PCE index and pending home sales data will be released at 10 a.m. ET.</li>
</ul>
No major economic reports are scheduled for Monday, Thursday, and Friday this week.
Stocks In Focus:
<ul>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42159139/microstrategy-shares-rise-in-monday-pre-market-as-michael-saylor-reveals-mstr-generating-500m-daily-amid-bitcoins-surge">stock surged</a> by more than 5% in premarket trading on Monday as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) inched closer to the $100,000 mark.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock was up nearly 7% in premarket trading after the company submitted a plan last week to be in compliance once again with the listing requirements to trade on the Nasdaq.</li>
<li>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) stock rose over 3.6% in premarket trading after the company was upgraded to "Outperform" by brokerage firm Wedbush.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock gained 3% in premarket trading after Wedbush <a href="https://www.benzinga.com/news/global/24/11/42156160/palantir-price-target-raised-to-75-by-dan-ives-amid-288-ytd-surge-analyst-calls-2025-a-primetime-year-for-ai">upgraded its price target</a> for the company to $75 from $57.</li>
<li>Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) stock surged 4% in premarket trading after analysts at Morgan Stanley increased the price target to $55 from $24.</li>
<li>Investors are awaiting earnings results from Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>), Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), and Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures fell in the early New York session, declining 0.29% to hover around $71.03.
The 10-year Treasury note yield eased to 4.351%.
Major Asian markets ended mixed on Monday, while European markets edged up in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42028334/bitcoin-ethereum-dogecoin-slip-as-feds-hawkish-stance-tempers-rally-analyst-expects-btc-to-reach-100k-before-new-year">Bitcoin, Ethereum, Dogecoin Slip As Fed&#8217;s Hawkish Stance Tempers Rally: Analyst Expects BTC To Reach $100K Before New Year</a></li>
</ul>
Photo courtesy: Wikimedia

Earnings

Equities

Futures

Economics

Federal Reserve

$BTC

BBWI

HOOD

MSTR

NVDA

PLTR

SMCI

SNOW

US Stocks Likely To Open On A Positive Note As Trump's Treasury Secretary Pick Uplifts Investor Sentiment: Expert Says 'Bull Market Is Alive And Well'

Boston Scientific expects to complete the transaction in the first half of 2025, subject to closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2025 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense.&nbsp;
Intera Oncology Inc., a privately held medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine – a chemotherapy drug – both of which are approved by the U.S. Food and Drug Administration. The Intera 3000 pump is used to administer hepatic artery infusion (HAI) therapy to treat tumors in the liver primarily caused by metastatic colorectal cancer.

Boston Scientific Enters Definitive Agreement To Acquire Privately Held Medical Device Company Intera Oncology; No Terms Disclosed

U-BX Technology Ltd. (the "Company" or "U-BX") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>), a leading company providing value-added&nbsp;services using artificial intelligence-driven&nbsp;technology to businesses within the insurance industry, including insurance carriers and brokers, today announced that it has resolved to effect a reverse stock split of the Company's ordinary shares and has determined the ratio to be 1-for-16. At the Company's annual meeting of shareholders held on October 24, 2024, the Company's shareholders approved a reverse stock split and granted the Company's Board of Directors the authority to determine the exact split ratio and on November 2, 2024, the Company's Board of Directors determined the ratio to be 1-for-16. U-BX's ordinary shares will begin trading on an adjusted basis giving effect to the reverse stock split on November 27, 2024 under the existing ticker symbol "UBXG". The new CUSIP number of the Company's ordinary shares will be G9161K112.
When the reverse stock split is effective, every sixteen shares of the Company's ordinary shares issued and outstanding as of the effective date will be automatically combined into one ordinary share. This will reduce the number of outstanding ordinary shares of U-BX from 29.7 million to approximately 1.9 million. Concurrently with the reverse stock split, the Company amended its Memorandum of Association to proportionately reduce the number of authorized ordinary for issuance and change the par value of post-reverse stock split ordinary shares to $0.0016 per share.
No fractional shares will be issued in connection with the reverse stock split. Shareholders otherwise entitled to receive a fractional share as a result of the reverse stock split will receive one full share.
Additional information concerning the reverse stock split can be found in U-BX's notice of annual general meeting filed with the Securities and Exchange Commission on October 8, 2024.

Stock Split

UBXG

U-BX Announces 1-for-16 Reverse Stock Split Effective November 27, 2024

UBS analyst Timothy Arcuri initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy rating and announces Price Target of $160.

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On ARM Holdings with Buy Rating, Announces Price Target of $160

BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) reported quarterly losses of $(0.00) per share which beat the analyst consensus estimate of $(0.05) by 98 percent. The company reported quarterly sales of $4.94 million which missed the analyst consensus estimate of $5.29 million by 6.57 percent.

BLRX

BioLine Rx Q3 2024 GAAP EPS $(0.00) Beats $(0.05) Estimate, Sales $4.94M Miss $5.29M Estimate

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, has finalized a $23.9 million award from the U.S. Department of Commerce to increase its compound semiconductor manufacturing capability and capacity at the Company's Albuquerque, New Mexico facility. The semiconductors produced by Rocket Lab are used in space-grade solar cells and other optoelectronic products that are important components for national security and commercial applications.

Government

Regulations

RKLB

Rocket Lab Secures $23.9M Grant to Boost Semiconductor Production in New Mexico

HC Wainwright &amp; Co. analyst Yi Chen reiterates Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) with a Buy and maintains $10 price target.

Reiteration

LEXX

HC Wainwright & Co. Reiterates Buy on Lexaria Bioscience, Maintains $10 Price Target

Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.16) by 75 percent. This is a 42.86 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $6.18 million which beat the analyst consensus estimate of $5.95 million by 3.93 percent. This is a 21.11 percent increase over sales of $5.11 million the same period last year.

Earnings Beats

CRGO

Freightos Q3 2024 Adj EPS $(0.04) Beats $(0.16) Estimate, Sales $6.18M Beat $5.95M Estimate

Telsey Advisory Group analyst Joseph Feldman downgrades Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) from Outperform to Market Perform and lowers the price target from $102 to $95.

Downgrades

FIVE

Telsey Advisory Group Downgrades Five Below to Market Perform, Lowers Price Target to $95

Summit Materials, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>), ("Summit," "Summit Materials," "Summit Inc." or the "Company") a leading producer of aggregates and cement, today announced it has entered into a definitive agreement to be acquired by&nbsp;Quikrete Holdings, Inc. ("Quikrete") for $52.50 per share in cash, for a total enterprise value of approximately $11.5 billion, including debt. The transaction price represents an approximately 36% premium to Summit's unaffected 90-day volume weighted average price (VWAP)1 and an approximately 29% premium to Summit's unaffected share price2. The combination has been unanimously approved by the Summit and Quikrete Boards of Directors.
&nbsp;
The transaction combines Summit's leading aggregates, cement and ready-mix concrete businesses with Quikrete's leading concrete and cement-based products business to create a vertically integrated, North American, construction materials solutions provider with strong customer relationships and iconic products.
"We are pleased to have reached this agreement which will deliver significant, immediate and certain cash value to our shareholders," said Howard Lance, Chairman of Summit's Board of Directors. "In reaching this decision, our Board carefully considered a range of alternatives and determined that this transaction is the best way to maximize value for our shareholders."
"This combination, and the value it creates, is a testament to our stellar strategic and financial performance, agile operational and commercial execution, and to the strength and talent of our entire team who have delivered a 34.6% annualized return since we began to develop our Elevate strategy on September 1, 2020," said Anne Noonan, Summit Materials President and Chief Executive Officer. "We believe this transaction will create new and exciting opportunities for our employees and customers. In Quikrete, we have found a strong partner that shares our commitment to safety and innovation, and we are excited to join forces with their team."
"We are thrilled to welcome Summit into the Quikrete family," said Will Magill, Chief Executive Officer of Quikrete. "This acquisition represents a significant milestone in our journey to expand our capabilities and geographic presence. Summit is a recognized leader with a highly complementary portfolio of trusted aggregate, cement and ready-mix solutions. We look forward to working closely with the talented team at Summit to achieve our shared vision for the future."
Approvals and Timing The transaction is expected to close in the first half of 2025, subject to Summit shareholder approval, regulatory approvals and other customary closing conditions. Upon completion of the transaction, Summit will become a privately held subsidiary of Quikrete and its common stock will no longer be traded on the NYSE.
Summit's largest shareholder, Cementos Argos, has entered into an agreement pursuant to which it has committed to vote all of its shares of Summit's common stock in favor of the transaction.
Quikrete has obtained commitment letters for the financing necessary to complete the transaction, which is not subject to a financing condition.
For further information regarding the terms and conditions contained in the definitive transaction agreement, please see Summit's current report on Form 8-K, which will be filed with the U.S. Securities and Exchange Commission in connection with the transaction.

Summit Materials to Be Acquired by Quikrete in $11.5B Deal

In the latest quarter, 5 analysts provided ratings for Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Eagle Materials, revealing an average target of $316.4, a high estimate of $330.00, and a low estimate of $290.00. This current average has increased by 6.1% from the previous average price target of $298.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1732536041_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Eagle Materials among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garik Shmois</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Hold</td>
<td>$315.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$317.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$309.00</td>
</tr>
<tr>
<td>Adrian Huerta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eagle Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eagle Materials compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Eagle Materials's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Eagle Materials's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eagle Materials analyst ratings.</a>
<h2>Delving into Eagle Materials's Background</h2>
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
<h3>Eagle Materials's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Eagle Materials's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.22% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: Eagle Materials's net margin excels beyond industry benchmarks, reaching 23.01%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Eagle Materials's ROE excels beyond industry benchmarks, reaching 10.32%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Eagle Materials's ROA stands out, surpassing industry averages. With an impressive ROA of 4.66%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Eagle Materials's debt-to-equity ratio surpasses industry norms, standing at 0.77. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Eagle Materials Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Molson Coors Beverage, revealing an average target of $61.0, a high estimate of $74.00, and a low estimate of $51.00. Marking an increase of 12.96%, the current average surpasses the previous average price target of $54.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732536034_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Molson Coors Beverage by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Grundy</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Vivien Azer</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$56.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molson Coors Beverage. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Molson Coors Beverage compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Molson Coors Beverage's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Molson Coors Beverage's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TAP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molson Coors Beverage analyst ratings.</a>
<h2>Unveiling the Story Behind Molson Coors Beverage</h2>
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the us, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the us, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
<h3>Unraveling the Financial Story of Molson Coors Beverage</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Molson Coors Beverage faced challenges, resulting in a decline of approximately -7.75% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Molson Coors Beverage's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 6.57%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Molson Coors Beverage's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.51%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Molson Coors Beverage's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.74%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Molson Coors Beverage's debt-to-equity ratio stands notably higher than the industry average, reaching 0.47. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Molson Coors Beverage

In the last three months, 10 analysts have published ratings on Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Palantir Technologies, revealing an average target of $42.9, a high estimate of $75.00, and a low estimate of $28.00. Marking an increase of 32.41%, the current average surpasses the previous average price target of $32.40. 
<img src="https://www.benzinga.com/files/images/story/2024/1732536028_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Palantir Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Latimore</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Underperform</td>
<td>$37.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Underperform</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mariana Perez</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Palantir Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Palantir Technologies compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Palantir Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Palantir Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PLTR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Palantir Technologies analyst ratings.</a>
<h2>Discovering Palantir Technologies: A Closer Look</h2>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. The Denver-based company was founded in 2003 and went public in 2020.
<h3>Palantir Technologies: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Palantir Technologies's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 29.98%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Palantir Technologies's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 19.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Palantir Technologies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 3.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Palantir Technologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 2.62%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Palantir Technologies's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Palantir Technologies's Future

Macy's Says A Single Employee With Responsibility For Small Package Delivery Expense Accounting Intentionally Made Erroneous Accounting Accrual Entries To Hide  $132M - $154M Of Cumulative Delivery Expenses From Q4 Of 2021 Through Fiscal Quarter Ended November 2, 2024

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $10.93, with a high estimate of $18.00 and a low estimate of $7.25. This current average represents a 28.19% decrease from the previous average price target of $15.22. 
<img src="https://www.benzinga.com/files/images/story/2024/1732536020_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Coursera by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bryan Smilek</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$7.25</td>
<td>$9.00</td>
</tr>
<tr>
<td>Yi Fu Lee</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sarang Vora</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Nafeesa Gupta</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$11.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Coursera. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Coursera compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Coursera's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Coursera's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COUR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coursera analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Coursera Better</h2>
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
<h3>Coursera: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Coursera's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 6.37%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Coursera's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -7.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.32%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.51%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Coursera adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COUR

What 11 Analyst Ratings Have To Say About Coursera

Across the recent three months, 25 analysts have shared their insights on Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Snowflake, revealing an average target of $179.76, a high estimate of $225.00, and a low estimate of $125.00. Witnessing a positive shift, the current average has risen by 7.17% from the previous average price target of $167.74.
<img src="https://www.benzinga.com/files/images/story/2024/1732536010_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Snowflake. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Announces</td>
<td>Outperform</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$185.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$172.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$186.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$183.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Buy</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Snowflake. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Snowflake compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Snowflake's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Snowflake's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Snowflake analyst ratings.</a>
<h2>Discovering Snowflake: A Closer Look</h2>
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that went public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to buy and ingest data, while its data solutions can be hosted on various public clouds.
<h3>Snowflake: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Snowflake's remarkable performance in 3 months is evident. As of 31 October, 2024, the company achieved an impressive revenue growth rate of 8.43%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -34.42%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Snowflake's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.19%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Snowflake's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.28%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Snowflake's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Snowflake Stands With Analysts

Citigroup analyst Keith Horowitz upgrades U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Neutral to Buy and raises the price target from $49 to $65.

Upgrades

Citigroup Upgrades U.S. Bancorp to Buy, Raises Price Target to $65

HC Wainwright &amp; Co. analyst Yi Chen downgrades Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) from Buy to Neutral.

MYNZ

HC Wainwright & Co. Downgrades Mainz Biomed to Neutral

As a result of the independent investigation and forensic analysis, the company identified that a single employee with responsibility for small package delivery expense accounting intentionally made erroneous accounting accrual entries to hide approximately $132 to $154 million of cumulative delivery expenses from the fourth quarter of 2021 through fiscal quarter ended November 2, 2024.
&nbsp;During this same time period, the company recognized approximately $4.36 billion of delivery expenses. There is no indication that the erroneous accounting accrual entries had any impact on the company's cash management activities or vendor payments.&nbsp;
The individual who engaged in this conduct is no longer employed by the company. The investigation has not identified involvement by any other employee.
&nbsp;

Macy's Says Identified An Issue Related To Delivery Expenses In One Of Its Accrual Accounts; Consequently Initiated An Independent Investigation

Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca's Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Overall survival (OS) data were immature at the time of this analysis; however, the Truqap combination showed an early trend towards an OS improvement versus abiraterone and ADT with placebo. The trial will continue as planned to further assess OS as a key secondary endpoint.
Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally.1 Only one third of patients with metastatic prostate cancer survive five years after diagnosis.2 Newly diagnosed mHSPC is an aggressive form of the disease associated with poor outcomes and survival.3,4 Approximately 200,000 patients are diagnosed with mHSPC each year, and one in four have PTEN-deficient tumours.5 Patients with a tumour biomarker of PTEN deficiency have a particularly poor prognosis.6
Karim Fizazi, MD, PhD, Institut Gustave Roussy, and University of Paris Saclay in Villejuif, France, and principal investigator for the trial said: "Patients with this aggressive form of prostate cancer with tumour PTEN deficiency currently face a particularly poor prognosis, and there is an urgent need for new treatments that improve upon current therapies. The results seen with capivasertib in combination with abiraterone-prednisone and androgen deprivation therapy in the CAPItello-281 trial represent a step forward for these patients."
Susan Galbraith, Executive Vice President, Oncology R&amp;D, AstraZeneca, said: "These results show for the first time, that adding an AKT inhibitor to a standard-of-care therapy can provide benefit to patients with a biomarker of PTEN-deficient metastatic hormone-sensitive prostate cancer. By targeting a key driver of the disease, we have been able to improve upon current therapies and demonstrate the potential role of this combination in an area of critical unmet need. It will be important to see greater maturity in key secondary endpoints including overall survival."
The safety profile of&nbsp;Truqap&nbsp;in combination with abiraterone and ADT in CAPItello-281 was broadly consistent with the known profile of each medicine.
Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
Notes
Prostate cancer Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally, with an incidence of more than 1.4 million and approximately 397,000 deaths in 2022.1
Metastatic prostate cancer is associated with a significant mortality rate, with only one third of patients surviving five years after diagnosis.2 Development of prostate cancer is often driven by male sex hormones called androgens, including testosterone.7
Metastatic hormone-sensitive prostate cancer In patients with mHSPC, also known as metastatic castration-sensitive prostate cancer (mCSPC), prostate cancer cells need high levels of androgens to drive cancer growth.4,7 Hormone therapies, such as ADT, are widely used to block the action of male sex hormones and lower the levels of androgens in the body.4,8 However, resistance to these therapies is common and there is a need to extend their use to delay disease progression and castration resistance, where the prostate cancer grows and spreads to other parts of the body despite the use of these therapies.3,4,8
In patients with de novo mHSPC, the cancer has spread to distant parts of the body at the time of first diagnosis.9
PTEN-loss or deficiency fuels the growth of cancer cells, leading to dysregulation of the PI3K/AKT pathway, and is associated with poor outcomes in patients with prostate cancer.6,10
CAPItello-281 CAPItello-281 is a Phase III, double-blind, randomised trial evaluating the efficacy and safety of Truqap in combination with abiraterone and ADT versus abiraterone and ADT in combination with placebo in the treatment of patients with PTEN-deficient de novo mHSPC.
The global trial enrolled 1,012 adult patients with histologically confirmed de novo hormone-sensitive prostate adenocarcinoma and PTEN deficiency as confirmed by central testing. The primary endpoint of the CAPItello-281 trial is rPFS as assessed by investigator, with OS as a secondary endpoint.
Truqap Truqap is a first-in-class, potent, adenosine triphosphate (ATP)-competitive inhibitor of all three AKT isoforms (AKT1/2/3). Truqap 400mg is administered twice daily according to an intermittent dosing schedule of four days on and three days off. This was chosen in early phase trials based on tolerability and the degree of target inhibition.
Truqap is approved in the US, EU, Japan and several other countries for the treatment of adult patients with HR-positive (or ER-positive), HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN) following recurrence or progression on or after an endocrine-based regimen based on the results from the CAPItello-291 trial. Truqap is also approved in Australia for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen based on these trial results.
Truqap is currently being evaluated in Phase III trials for the treatment of breast cancer (CAPItello-292) and prostate cancer (CAPItello-280 and CAPItello-281) in combination with established treatments.
Truqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited).
AstraZeneca in oncology AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca's Truqap Demonstrates Progress in Advanced Prostate Cancer Treatment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning!



Moving stocks today are a new patent, new agreements, delisting news, a proposed public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Agrify (NASDAQ:<a href="https://investorplace.com/stock-quotes/agfy-stock-quote/">AGFY</a>) stock is rocketing more than 56% alongside heavy pre-market trading.</li>



<li>Sunrise New Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/epow-stock-quote/">EPOW</a>) shares are soaring over 36% after being <a href="https://www.nasdaq.com/press-release/sunrise-new-energys-lithium-ion-battery-patent-granted-key-funding-guizhou-province">granted a new battery patent funding</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) stock is surging close to 32% without any clear news this morning.</li>



<li>Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) shares are gaining more than 27% with heavy early morning trading today.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is increasing over 23% despite a lack of news this morning.</li>



<li>Delta Apparel (NYSEMKT:<a href="https://investorplace.com/stock-quotes/dla-stock-quote/">DLA</a>) shares are heading more than 19% higher on Monday morning.</li>



<li>Unusual Machines (NYSEMKT:<a href="https://investorplace.com/stock-quotes/umac-stock-quote/">UMAC</a>) stock is rising 19% <a href="https://www.nasdaq.com/press-release/correction-source-unusual-machines-selected-provide-first-drone-red-cats-fangtm-line">on a drone agreement</a>.</li>



<li>Bitcoin Depot (NASDAQ:<a href="https://investorplace.com/stock-quotes/btm-stock-quote/">BTM</a>) shares are climbing over 15% this morning.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is jumping 15% on a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-holdings-limited-announces-launch-new-investment-relationship">new investment relationship</a>.</li>



<li>Denali Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/deca-stock-quote/">DECA</a>) shares are up more than 14% on Monday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>BitFuFu (NASDAQ:<a href="https://investorplace.com/stock-quotes/fufu-stock-quote/">FUFU</a>) stock is diving over 27% after a major rally on Friday.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are tumbling more than 25% ahead of its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318404814&amp;type=PDF&amp;symbol=DMTK&amp;cdn=2f95604b7d0b2db1ef0d52c1cc04ae14&amp;companyName=DermTech+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">delisting later this week</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is taking a 25% beating <a href="https://www.nasdaq.com/press-release/american-rebel-signs-distribution-agreement-dichello-distributors-state-connecticut">following a Friday rally</a>.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares are retreating over 17% after jumping in the <a href="https://investorplace.com/2024/06/why-is-36kr-krkr-stock-up-17-today/">previous day of trading</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is sliding more than 17% as it <a href="https://investorplace.com/2024/06/why-is-professional-diversity-network-ipdn-stock-down-22-today/">continues negative movement</a>.</li>



<li>G1 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) shares are falling nearly 17% alongside a <a href="https://www.nasdaq.com/press-release/g1-therapeutics-provides-update-phase-3-preserve-2-trial-patients-receiving">Phase 3 clinical trial update</a>.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) stock is dropping over 16% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318408657&amp;type=PDF&amp;symbol=ALLR&amp;cdn=2b98061f2188998b482fa6052ee2392c&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=PRE+14A&amp;formDescription=Preliminary+proxy+statement+providing+notification+matters+to+be+brought+to+a+vote&amp;dateFiled=2024-06-21">shareholder meeting plans</a>.</li>



<li>Spectaire (NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/">SPEC</a>) shares are decreasing more than 14% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318408996&amp;type=PDF&amp;symbol=SPEC&amp;cdn=3890204bdd59982142fb7ff1035bfa7b&amp;companyName=Spectaire+Holdings+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-06-21">proposed public offering</a>.</li>



<li>Inuvo (NYSEMKT:<a href="https://investorplace.com/stock-quotes/inuv-stock-quote/">INUV</a>) stock is slipping over 14% today.</li>



<li>Molecular Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/">MOLN</a>) shares close out our pre-market stock movers down more than 13% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!



Moving stocks this morning are earnings reports, insider buying, offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 78% alongside heavy pre-market trading.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are soaring over 47% with strong early morning trading.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is surging more than 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318411360&amp;type=PDF&amp;symbol=GLYC&amp;cdn=8f7645b9da4ce31c36360d7737c007dc&amp;companyName=GlycoMimetics+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-24">alongside insider buying</a>.</li>



<li>Anew Medical (OTCMKTS:<a href="https://investorplace.com/stock-quotes/leas-stock-quote/">LEAS</a>) shares are gaining over 38% without any clear news this morning.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) shares are increasing more than 24% with strong pre-market trading.</li>



<li>Regis (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgs-stock-quote/">RGS</a>) stock is rising over 21% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318412499&amp;type=PDF&amp;symbol=RGS&amp;cdn=4f01bbb678bba4ddafaac79f77ec0544&amp;companyName=Regis+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-25">senior secured credit facility</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are heading close to 20% higher with heavy pre-market trading today.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is jumping more than 17% <a href="https://www.nasdaq.com/press-release/kaival-brands-announces-closing-60-million-public-offering-2024-06-24">after closing a public offering</a>.</li>



<li>BioXcel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/btai-stock-quote/">BTAI</a>) shares are climbing over 13% on <a href="https://www.nasdaq.com/press-release/bioxcel-therapeutics-announces-positive-topline-results-post-marketing-requirement">topline results from a study</a>.</li>



<li>Captivision (NASDAQ:<a href="https://investorplace.com/stock-quotes/capt-stock-quote/">CAPT</a>) stock is up more than 12% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is plummeting over 25% on plans for a <a href="https://finance.yahoo.com/news/faraday-future-announces-plans-regaining-215900667.html">reverse stock split</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) shares are diving more than 22% after a massive rally yesterday.</li>



<li>Beyond Air (NASDAQ:<a href="https://investorplace.com/stock-quotes/xair-stock-quote/">XAIR</a>) stock is tumbling over 19% on <a href="https://finance.yahoo.com/news/beyond-air-inc-xair-reports-212503389.html">lackluster Q4 earnings</a>.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are retreating more than 19% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-113-today/">after rallying yesterday</a>.</li>



<li>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) stock is taking an over 16% beating on a <a href="https://www.nasdaq.com/press-release/solaredge-technologies-inc-announces-proposed-private-offering-300-million">$300 million private offering</a>.</li>



<li>IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) shares are dropping more than 16% on its <a href="https://www.nasdaq.com/press-release/igc-reports-financial-results-fiscal-year-ended-march-31-2024-2024-06-24">latest earnings report</a>.</li>



<li>Oragenics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ogen-stock-quote/">OGEN</a>) stock is falling over 15% on a <a href="https://www.stocktitan.net/news/OGEN/oragenics-inc-announces-proposed-public-688vwqnwez4o.html">proposed public offering</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are decreasing nearly 12% after a <a href="https://www.nasdaq.com/press-release/dermtech-files-voluntary-chapter-11-protection-2024-06-18">recent bankruptcy filing</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is slipping more than 11% with recent weakness.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

36Kr partners with Zhi-Tech Group to expand business

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc. has announced a significant shift in its management team, with Ms. Lin Wei step...

36Kr Holdings Inc. Appoints New CFO

36Kr Holdings GAAP EPADS of -$0.31, revenue of $14.09M

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc., a leading New Economy platform in China, has reported a 9.2% increase in its f...

36Kr Holdings Inc. Navigates Economic Challenges

36Kr Holdings Inc. (KRKR) Q2 2024 Earnings Call Transcript

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc., a key player in China's New Economy sector, has announced a plan to modify its...

36Kr Holdings Inc. Announces ADS Ratio Change

36Kr Holdings Inc (KRKR) has released an update. 36Kr Holdings Inc. has successfully regained compliance with Nasdaq's minimum bid price rule after...

36Kr Holdings Inc. Secures Nasdaq Compliance

36Kr Holdings (KRKR) announced that it has recently teamed up with Soften Corporation to launch a news hub, the "36Kr Market Watch" WeChat mini pro...

36Kr Holdings partners with Soften Corporation to launch a news hub

AGFY

ALLR

BTAI

CAPT

COOT

DECA

EPOW

FFIE

FUFU

GLYC

GTHX

INUV

LEAS

MLGO

NCPL

NUKK

OGEN

RDZN

SEDG

SNTI

UMAC

VLCN

XAIR

Press Releases

36Kr Holdings Inc. Files 2023 Annual Report on Form 20-F

36Kr Hosts "AI Partner • Advanced Productivity" Conference

Contracts

36Kr Enters into Strategic Partnership with SenseTime to Pioneer AGI Innovation

Virtual Production Market Set for Significant Expansion Driven by Technological Innovations & Shifts in Media Consumption Habits

36Kr Partners with Consumer Tech Expert Zhi-Tech Group to Drive Business Expansion

Management

36Kr Holdings Inc. Announces Changes to Management and Board of Directors

36Kr Holdings Inc. to Report 2024 First Half Financial Results on Tuesday, September 3, 2024

36Kr Holdings Inc. Reports Unaudited Financial Results for the First Half of 2024

General

36Kr Further Expands Global Reach, Bringing Awareness of China's Economy Worldwide

36Kr and Soften Partner to Launch Innovative News Hub

FOXA

Angi

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

Bumble

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

EverQuote

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Phoenix New Media

Comments

36KR Holdings

36KR Holdings (KRKR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga